Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report highlighted an instance of lichen spinulosus emerging as a new cutaneous sequela in a boy following toxic epidermal necrolysis, responding to treatment with ammonium lactate.

This report documented a case of thrombocytopenia and leukopenia linked to the long-term use of itraconazole in a patient with acute myelogenous leukemia.

In this study on tolerant rats, maternal and developmental toxicity from levo-alpha-acetyhnethadol hydrochloride were observed at all doses, without specific fetal toxicity or teratogenic effects.

This letter discusses the potential of the Janus kinase 1 inhibitor abrocitinib for treating oral lichen planus but provides no new research findings.

In this phase I study, CT-707, a new ALK inhibitor, showed a 77% response rate among Chinese patients with advanced ALK-rearranged non-small cell lung cancer, suggesting clinical effectiveness despite some adverse events like diarrhea and liver enzyme elevation.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This study found that combining bromhexine and spironolactone was effective in improving clinical outcomes and reducing viral load or hospitalization duration in patients with mild to moderate COVID-19.

Repaglinide-loaded liponiosomal hybrids improve blood sugar control and insulin release better than regular Repaglinide.

In this study, reversible ageusia in a patient was strongly suggested to be caused by losartan, with potential implications for angiotensin receptor involvement in taste disturbance.

This case report describes successful treatment of valproate-induced hyperammonemia in a 79-year-old man using lactulose, marking the first such documented use for this condition.

This report describes a case where rituximab provided durable remission in a patient with refractory aggressive diffuse B-cell lymphoma that was unresponsive to prior chemotherapy.

This study found that treatment with Shunyou dispersible tablet and prednisone improved clinical symptoms in patients with lupus nephritis, showing significant benefits over time along with a good safety profile.

This study found that stilbamidine and hydroxystilbamidine can inhibit the release of specific enzymes from lysosomes and mitochondria in rabbit liver at certain concentrations, with effects similar to cortisol and chloroquine.

In this retrospective study of adolescents with recalcitrant cutaneous lupus, lenalidomide treatment resulted in complete or near resolution of skin symptoms within 6 months, while allowing for a reduction in prednisone dosage.

This study found that the herbal combination PRO 160/120 significantly improved nocturnal voiding frequency in patients with moderate-to-severe LUTS/BPH compared to placebo, with similar effectiveness to tamsulosin and finasteride.

This study reports that a novel Nano-Structured Lipid Carrier system for delivering dutasteride may enhance its anticancer effects while reducing systemic side effects in clinical settings.

This report details two cases of Lichen spinulosus in the submental area, treated effectively and safely with topical tacalcitol cream.

In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.

In this study, bicalutamide at low doses was not linked to significant liver enzyme changes compared to other androgen-blocking treatments in transfeminine adolescents and young adults, suggesting its safety with careful monitoring for this population over one year.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

This study found that oral tofacitinib improved disease activity in patients with lichen planopilaris, suggesting it may be a promising treatment option for this condition.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

In this randomized study, BAY 1158061, a prolactin receptor antibody, was found to be safe, well-tolerated, and exhibited low immunogenicity in healthy postmenopausal women, but had no effect on serum prolactin levels compared to placebo.

This study found that compound 4 from Urtica triangularis subsp. pinnatifida exhibited stronger anti-BPH activity against BPH-1 cells with an IC50 of 79.75 μM compared to finasteride's IC50 of 91.8 μM, while compounds 1, 2, and 5 showed moderate activity.

Lactium, a milk protein, can help reduce symptoms of skin disorders linked to stress and anxiety without side effects.

This source notes that Olumiant (baricitinib), a rheumatoid arthritis drug by Eli Lilly and Company, has been approved as the first systemic treatment for severe alopecia areata.

This article describes cutaneous reactions including keratosis pilaris-like eruptions in a patient on nilotinib for chronic myelogenous leukemia, emphasizing the importance of accurately classifying such eruptions.

This open-label study suggests that combining valproate, lamotrigine, and a benzodiazepine can significantly reduce the frequency of epileptic drop attacks in patients with generalized or multifocal epilepsies.